The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
(2022)
Journal Article
Ivell, R., Heng, K., Severn, K., Antonio, L., Bartfai, G., Casanueva, F. F., Huhtaniemi, I. T., Giwercman, A., Maggi, M., O’Connor, D. B., O’Neill, T. W., Punab, M., Rastrelli, G., Slowikowska-Hilczer, J., Tournoy, J., Vanderschueren, D., Wu, F. C. W., & Anand-Ivell, R. (2022). The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort. Frontiers in Endocrinology, 13, Article 1016107. https://doi.org/10.3389/fendo.2022.1016107
Background: Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation sta... Read More about The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort.